Related Experiment Videos
Metformin and blood pressure
1Department of Medicine II, University of Göteborg, Sahlgrenska Hospital, Sweden.
Journal of Clinical Pharmacy and Therapeutics
|April 1, 1992
Summary
Metformin treatment in hypertensive patients improved insulin sensitivity and reduced blood pressure. This suggests insulin resistance may play a key role in primary hypertension and related metabolic issues.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Hypertension is a significant risk factor for cardiovascular diseases like stroke and coronary artery disease.
- Insulin resistance and hyperinsulinemia are frequently observed in hypertensive individuals, regardless of obesity status.
- Primary hypertension may involve underlying metabolic and fibrinolytic abnormalities.
Purpose of the Study:
- To investigate the potential of metformin, an antidiabetic agent, in improving insulin sensitivity in non-obese, non-diabetic, untreated hypertensive patients.
- To explore the role of insulin resistance in the development and management of primary hypertension.
Main Methods:
- A pilot study administered metformin to non-obese, non-diabetic, untreated hypertensive individuals.
- Evaluated changes in insulin sensitivity, plasma insulin levels, lipid profiles, fibrinolytic activity, and blood pressure.
Main Results:
- Metformin significantly improved insulin sensitivity and decreased plasma insulin levels.
- Treatment with metformin led to reductions in serum cholesterol and triglycerides.
- A marked decrease in blood pressure and an increase in fibrinolytic activity were observed.
Conclusions:
- Insulin resistance may be a crucial factor in primary hypertension, often accompanied by metabolic and fibrinolytic abnormalities.
- The findings suggest that insulin resistance might precede the onset of hypertension in susceptible individuals.
- Metformin shows potential as a therapeutic agent for managing hypertension associated with insulin resistance.